NCT02839265View on ClinicalTrials.gov

FLT3 Ligand Immunotherapy and Stereotactic Radiotherapy for Advanced Non-small Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL

Enrollment

33

Participants

Timeline

Start Date

July 31, 2016

Primary Completion Date

October 5, 2022

Study Completion Date

November 22, 2024

Conditions

Non-small Cell Lung Cancer (NSCLC)

Interventions

DRUG

FLT3 Ligand Therapy (CDX-301)

See Arm 1 descriptions

RADIATION

Stereotactic Body Radiotherapy (SBRT)

See Arm 1 descriptions

Trial Locations (1)

10467

Montefiore Medical Center, The Bronx

Sponsors

Collaborators (1)

Celldex Therapeutics

All Listed Sponsors

collaborator

Celldex Therapeutics

INDUSTRY

lead

Albert Einstein College of Medicine

OTHER

NCT02839265 - FLT3 Ligand Immunotherapy and Stereotactic Radiotherapy for Advanced Non-small Cell Lung Cancer | Biotech Hunter | Biotech Hunter